Cytokines, Breast Cancer Stem Cells (BCSCs) and Chemoresistance

Overview

Journal Clin Transl Med

Publisher Wiley

Specialty General Medicine

Date 2018 Sep 4

PMID 30175384

Citations 54

Authors

Weilong Chen

Yuanyuan Qin

Suling Liu

Affiliations

Soon will be listed here.

Abstract

Chemotherapy resistance of breast cancer poses a great challenge to the survival of patients. During breast cancer treatment, the development of intrinsic and acquired drug resistance tends to further induce adverse prognosis, such as metastasis. In recent years, the progress of research on cytokine-modulated tumor microenvironment and breast cancer stem cells (BCSCs) has shed light on defining the mechanisms of drug resistance gradually. In this review, we have discussed cytokine regulation on breast cancer chemoresistance. Cytokines can affect tumor cell behavior or reprogram tumor niche through specific signaling pathways, thereby regulating the progress of drug resistance. In addition, we summarized the mutually regulatory networks between cytokines and BCSCs in mediating chemoresistance. Cytokines in the tumor microenvironment can regulate the self-renewal and survival of BCSCs in a variety of ways, sequentially promoting chemotherapeutic resistance. Therefore, the combinational treatment of BCSC targeting and cytokine blockade may have a positive effect on the clinical treatment of breast cancer.

Citing Articles

Elucidating the Role of Estrogen Effects in Leukemia: Insights from Single-Cell RNA Sequencing and Mendelian Randomization.

Zhao J, Yu Y, Liu C, Liu R, Sun M, Zhuang J J Cancer. 2025; 16(3):888-897.

PMID: 39781360 PMC: 11705057. DOI: 10.7150/jca.100610.

Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer.

Mussa A, Ismail N, Hamid M, Al-Hatamleh M, Bragoli A, Hajissa K J Exp Clin Cancer Res. 2024; 43(1):312.

PMID: 39609700 PMC: 11603874. DOI: 10.1186/s13046-024-03218-1.

Cancer cell targeting by CAR-T cells: A matter of stemness.

DAccardo C, Porcelli G, Mangiapane L, Modica C, Pantina V, Roozafzay N Front Mol Med. 2024; 2:1055028.

PMID: 39086964 PMC: 11285689. DOI: 10.3389/fmmed.2022.1055028.

The obese inflammatory microenvironment may promote breast DCIS progression.

Habanjar O, Nehme R, Goncalves-Mendes N, Cueff G, Blavignac C, Aoun J Front Immunol. 2024; 15:1384354.

PMID: 39072314 PMC: 11272476. DOI: 10.3389/fimmu.2024.1384354.

Coordinated inflammation and immune response transcriptional regulation in breast cancer molecular subtypes.

Velazquez-Caldelas T, Zamora-Fuentes J, Hernandez-Lemus E Front Immunol. 2024; 15:1357726.

PMID: 38983850 PMC: 11231215. DOI: 10.3389/fimmu.2024.1357726.

References

Kakarala M, Wicha M . Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol. 2008; 26(17):2813-20. PMC: 2789399. DOI: 10.1200/JCO.2008.16.3931. View

Sharma B, Varney M, Saxena S, Wu L, Singh R . Induction of CXCR2 ligands, stem cell-like phenotype, and metastasis in chemotherapy-resistant breast cancer cells. Cancer Lett. 2016; 372(2):192-200. PMC: 4821546. DOI: 10.1016/j.canlet.2015.12.011. View

Lin X, Chen W, Wei F, Zhou B, Hung M, Xie X . Nanoparticle Delivery of miR-34a Eradicates Long-term-cultured Breast Cancer Stem Cells via Targeting C22ORF28 Directly. Theranostics. 2017; 7(19):4805-4824. PMC: 5706101. DOI: 10.7150/thno.20771. View

Xing F, Liu Y, Sharma S, Wu K, Chan M, Lo H . Activation of the c-Met Pathway Mobilizes an Inflammatory Network in the Brain Microenvironment to Promote Brain Metastasis of Breast Cancer. Cancer Res. 2016; 76(17):4970-80. PMC: 5010459. DOI: 10.1158/0008-5472.CAN-15-3541. View

Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G . TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene. 2014; 34(6):681-90. DOI: 10.1038/onc.2014.5. View

Kim S, Kim H, Lee D, Kim T, Kim T, Chung C . Reversing the intractable nature of pancreatic cancer by selectively targeting ALDH-high, therapy-resistant cancer cells. PLoS One. 2013; 8(10):e78130. PMC: 3806801. DOI: 10.1371/journal.pone.0078130. View

Ireland L, Santos A, Campbell F, Figueiredo C, Hammond D, Ellies L . Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer. Oncogene. 2018; 37(15):2022-2036. PMC: 5895608. DOI: 10.1038/s41388-017-0115-x. View

Singh J, Simoes B, Howell S, Farnie G, Clarke R . Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res. 2013; 15(4):210. PMC: 3978717. DOI: 10.1186/bcr3436. View

Ohlund D, Elyada E, Tuveson D . Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014; 211(8):1503-23. PMC: 4113948. DOI: 10.1084/jem.20140692. View

10.

Kalluri R . The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016; 16(9):582-98. DOI: 10.1038/nrc.2016.73. View

11.

Lee K, Yeo S, Sung C, Kim S . Twist1 is a key regulator of cancer-associated fibroblasts. Cancer Res. 2014; 75(1):73-85. DOI: 10.1158/0008-5472.CAN-14-0350. View

12.

Tam W, Lu H, Buikhuisen J, Soh B, Lim E, Reinhardt F . Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell. 2013; 24(3):347-64. PMC: 4001722. DOI: 10.1016/j.ccr.2013.08.005. View

13.

Kim S, Kang J, Song X, Kim B, Yoo Y, Kwon Y . Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal. 2013; 25(4):961-9. PMC: 3595341. DOI: 10.1016/j.cellsig.2013.01.007. View

14.

Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S . Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell. 2010; 140(1):62-73. DOI: 10.1016/j.cell.2009.12.007. View

15.

Wang P, Weng C, Hou Y, Jian S, Fang K, Hou M . Activation of VCAM-1 and its associated molecule CD44 leads to increased malignant potential of breast cancer cells. Int J Mol Sci. 2014; 15(3):3560-79. PMC: 3975354. DOI: 10.3390/ijms15033560. View

16.

Chang J, Mani S . Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition. Cancer Lett. 2013; 341(1):16-23. PMC: 3762892. DOI: 10.1016/j.canlet.2013.03.004. View

17.

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

18.

Elizondo G, Medina-Diaz I, Cruz R, Gonzalez F, Vega L . Retinoic acid modulates retinaldehyde dehydrogenase 1 gene expression through the induction of GADD153-C/EBPbeta interaction. Biochem Pharmacol. 2008; 77(2):248-57. PMC: 2790144. DOI: 10.1016/j.bcp.2008.10.011. View

19.

Sun J, Luo Q, Liu L, Song G . Liver cancer stem cell markers: Progression and therapeutic implications. World J Gastroenterol. 2016; 22(13):3547-57. PMC: 4814640. DOI: 10.3748/wjg.v22.i13.3547. View

20.

Esquivel-Velazquez M, Ostoa-Saloma P, Palacios-Arreola M, Nava-Castro K, Castro J, Morales-Montor J . The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res. 2014; 35(1):1-16. PMC: 4291218. DOI: 10.1089/jir.2014.0026. View